The company's approach involves understanding and leveraging the mechanisms and properties of their drug candidates to optimize efficacy and tolerability for cancer patients. They have multiple pipeline candidates with unique mechanisms of action that target pathways involved in various hematological malignancies and solid tumors. MEI Pharma's ongoing clinical trials include evaluating Zandelisib for B-cell malignancies, Voruciclib for hematologic malignances and solid tumors, and ME-344 for solid tumors. They are also collaborating with Helsinn Group on the clinical development of Pracinostat for high-risk myelodysplastic syndrome. MEI Pharma is committed to upholding workplace values of dedication, shared commitment, personal accountability, mutual trust, and fiscal discipline.